🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

359 results for “vaccine” Clear

  1. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  2. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  3. meningococcal ACWY (vaccine)

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 mab completed

    1 trial

  4. middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 2 mab active

    1 trial

  5. p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine

    INOVIO PHARMACEUTICALS, INC.

    Leukaemia (Acute)

    phase 2 mab completed

    1 trial

  6. pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    Anatomic Stage I Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  7. pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Sinovac Research and Development Co.,

    Pandemic Influenza

    phase 2 mab completed

    1 trial

  8. pepinemab + pembrolizumab

    VACCINEX, INC.

    Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

    phase 2 small molecule completed

    1 trial

  9. pneumococcal polysaccharide and protein conjugate vaccines

    United Therapeutics Europe Ltd

    Pneumococcal Infections

    phase 2 mab completed

    1 trial

  10. split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Influenza

    phase 2 mab completed

    2 trials

  11. 100U inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Hand-foot-mouth Disease

    phase 1 mab completed

    1 trial

  12. 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV Infection

    phase 1 mab completed

    1 trial

  13. 15-Valent Pneumococcal Conjugate Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Pneumonia, Pneumococcal

    phase 1 mab active

    1 trial

  14. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

  15. A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)

    The George Institute

    Crimean Congo Hemorrhagic Fever

    phase 1 other active

    1 trial

  16. A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.

    The George Institute

    Prevention of Cholera disease

    phase 1 other active

    1 trial

  17. A clinical study of the V540A vaccine in healthy adults (V540A-001)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  18. A clinical study of the V540C vaccine in healthy adults (V540C-003)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  19. A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

    Teva Pharma GmbH

    Influenza

    phase 1 other active

    1 trial

  20. A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

    Teva Pharma GmbH

    Pneumococcal infection

    phase 1 other active

    1 trial

  21. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  22. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  23. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  24. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Colon Carcinoma Metastatic in the Liver

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources